The International Antiviral Society published updated 2020 recommendations on use of antiretroviral therapy, laboratory monitoring and screening, prevention, and management of older patients living with HIV.
Investigators conducted a prospective analysis in patients with HIV to assess the rate of switching from TDF-based to TAF-based or dual therapy regimens and to assess the impact of switching on eGFR.
A major concern in people with HIV includes accelerated atherosclerosis, underlined by increased rates of coronary artery disease. Researchers investigated the longitudinal progression of atherosclerosis in persons with HIV vs without HIV in the Swiss population.
Researchers assessed the risk of diabetes mellitus, weight gain, and their relationships with integrase inhibitor-based initial antiretroviral therapy among persons with HIV in the United States and Canada.
Researchers conducted a retrospective cohort study to analyze national trends in drug payments and other associated costs of HIV PrEP treatment.
Patients with persistent ALT elevation despite controlled HBV should undergo evaluation for metabolic risk and fatty liver disease.
Researchers evaluated the results of multiple phase 2 and phase 3 clinical trials and found that drug resistance to darunavir, an HIV protease inhibitor, is rare.
In post-hoc analyses, researchers analyzed alcohol use data and whole-blood samples from 359 participants in the New Orleans Alcohol Use in HIV study to explore the association between intestinal leak, dysbiosis, and T cells.
A cross-sectional study was performed to assess whether age, body mass index, and/or components of antiretroviral therapy contributed to persistence of HIV viremia.
Fenway Health has created a PrEP Action Kit that provides a roadmap for other health care organizations to implement and/or advance existing PrEP prescription programs.
